J Korean Oncol Nurs.  2011 Feb;11(1):58-64.

Compliance with the Protocol Considered Emetogenic Potential for Prophylaxis of Chemotherapy Induced Nausea and Vomiting

• Choi JY
• Oh HJ
• Kang JY
• Kim MK
• Kim JE
• Kim JH
• Kim HS
• Park SR
• Byun JS
• An JH
• Cho MK

Abstract

PURPOSE
The purpose of this study was to identify the compliance with the protocol, which was developed considering the emetogenic potential for prophylaxis of chemotherapy.
METHODS
Data was collected from 144 patients who received chemotherapy from June 15 to August 31, 2010 in C University Hospital in Jeollanamdo, Korea. The level of chemotherapy-induced nausea and vomiting (CINV) and the compliance with the protocol for prophylaxis of CINV were measured.
RESULTS
There was statistically significant difference of CINV in morning sickness and anticipatory nausea of general and clinical characteristics. Also, the compliance with the protocol developed according to emetogenic potential of chemotherapy was statistically significant. There was no difference in CINV in regard to the compliance with the protocol.
CONCLUSION
There was a good compliance with the protocol for prophylaxis according to emetogenic potential. But it should be recommended to use antiemetics for prophylaxis aggressively to relieve CINV for the patients who already experienced morning sickness and anticipatory nausea. In addition, the oncology nurses should respond sensitively to the complaints of nausea and vomiting no matter what the emetogenic potentials of chemotherapy regimen are.

Keyword

Guideline Adherence; Antineoplastic combined chemotherapy protocols; Nausea; Vomiting

MeSH Terms

Antiemetics
Antineoplastic Combined Chemotherapy Protocols
Compliance
Female
Guideline Adherence
Humans
Korea
Morning Sickness
Nausea
Pregnancy
Vomiting
Antiemetics

Reference

1. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, et al. Cancer statistics in Korea: Incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010. 25:1113–1121.

2. Jordan K, Sippel C, Schmoll HH. Guidelines for antiemetic treatment of chemotherapy induced nausea and vomiting: past. present, future recommendations. Oncologist. 2007. 12:1143–1150.

3. Oh CY, Yun HY, Lim EH, Kim ON. Evaluation of antiemetic therapy after the administration of high-dose antineoplastic agents: Focused Ondansetron. J Korean Soc Health Syst Pharm. 1999. 16:495–500.

4. Kwon SJ. A recommendation of antiemetics. Korean J Clin Oncol. 2006. 2:30–35.

5. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006. 24:2932–2947.

6. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997. 15:103–109.

7. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006. 24:2932–2947.

8. Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol. 1998. 9:811–819.

9. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999. 17:2971–2994.

10. European Society for Medical Oncology. ESMO recommendations for prophylaxis of chemotherapy-induced nauseaand vomiting (NV). Ann Oncol. 2001. 12:1059–1060.

11. National Comprehensive Cancer Network. Effective interventions for CINV: NCCN Antiemesis Clinical Practice Guidelines in Oncology. ONS News. 2004. 19:9 Suppl. 17–18.

12. Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol. 2008. 19:Suppl 2. ii110–ii112.

13. Asan Medical Center Cancer Center. Clinical practice guideline for Chemotherapy. 2009. Seoul: Koonja publishers.

14. Wickham R. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Support Oncol. 2010. 8:2 Suppl 1. 10–15.

15. Shih V, Wan HS, Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother. 2009. 43:444–452.

16. Warr DG. Chemotherapy- and cancer-related nausea and vomiting. Curr Oncol. 2008. 15:Suppl 1. S4–S9.

17. Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, et al. Improving the care of patients with regard to chemotherapy induced nasuea and emesis: The effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol. 2003. 21:1373–1378.

18. Rhodes VA. Criteria for assessment of nausea, vomiting, and retching. Oncol Nurs Forum. 1997. 24:7 Suppl. 13–19.

19. Rhodes VA, Mcdaniel RW. The index of nausea, vomiting and retching: a new format of the Index of Nausea and Vomiting. Oncol Nurs Forum. 1999. 26:889–894.

20. Kim YJ, Kim JY, Choi IR, Kim MW, Rhodes VA. The index of nausea, vomiting and retching(Korean translation). J Korean Acad Adult Nurs. 2000. 12:278–285.

21. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care cancer. 2001. 10:139–145.

22. Molassiotis A, Brearley SG, Stamataki Z. Use of antiemtics in the management of chemotherapy-related nausea and vomiting in current UK practice. Support Care Cancer. arcessed on 2 June 2010. Available at: http://www.springerlink.com/content/lg36372wlx3587p0/.

23. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004. 15:526–536.

24. Grélot L, Dapzol J, Estève E, Frugière A, Bianchi AL, Sheldrick RL, et al. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist. Br J Pharmacol. 1998. 124:1643–1650.